Allogeneic NK platform technology targeting solid and blood based cancers… that ticks a lot of boxes!
pipeline is young, but now even more promising… with combination therapies going into development using our CLTX CAR-T.
trials expected to commence in 2023, so still a while away.. but still a lot of preclinical newsflow to derisk the asset between now and then.
plenty more reading material over the summer!
great company in the making, with opportunities to accumulate before CLTX cohort 2 data lands mid 2022… which couldn’t come soon enough.
goodluck all
Ann: Transformative Portfolio Expansion Presentation, page-3
-
- There are more pages in this discussion • 3 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Add CHM (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
1.6¢ |
Change
-0.001(5.88%) |
Mkt cap ! $14.18M | |||
| Open | High | Low | Value | Volume |
| 1.8¢ | 1.8¢ | 1.6¢ | $9.273K | 548.5K |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 10 | 1365817 | 1.6¢ |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| 1.7¢ | 24633 | 1 |
View Market Depth
| Last trade - 16.10pm 08/08/2024 (20 minute delay) ? |
| CHM (ASX) Chart |